Objective To explore and compare the clinical curative effect of tocilizumab and leflunomide in the treatment of rheumatoid arthritis and to evaluate the safety. Methods From March 2015 to March 2016,70 cases of rheumatoid arthritis treated in the department of rheumatism in this hospital were divided into treatment group and control group by using a random number table method,35 cases in each group.The patients in the observation group were intravenously treated with tocilizumab,at dosage of 8 mg·kg-1,once every four weeks.The control group was treated by oral administration of leflunomide tablets,at 50 mg·d-1from the 1st to 3rd day,and at 20 mg·d-1from the fourth day to the end of the treatment.The treatment period was 24 weeks in the two groups.Joint swelling,joint pain,morning stiffness,ESR,CRP,IL-6 and IL-8 were recorded and compared before and during the treatment.Total effective rate of treatment was compared between the two groups.Adverse drug reaction was recorded and the incidence of adverse drug reactions was compared. Results After the treatment,joint swelling, joint pain,morning stiffness,ESR,CRP,IL-6 and IL-8 were significantly lower in the treatment group than those in the control group (P<0.05).After the treatment,the total effective rate of the treatment was significantly higher than that of the control group (P<0.05).After the treatment,incidence of adverse reaction was significantly lower in the treatment group than that in the control group(P<0.05). Conclusion Tocilizumab and leflunomide has certain curative effect in the treatment of rheumatoid arthritis, but tocilizumab is more effective,with low incidence of adverse reaction and a high clinical value.

[Abstract] Objective: To investigate the effect of Tim-4 on invasion and migration of cervical cancer cells and its underlying mechanisms. Methods：The expression levels of Tim-4 in cervical cancer cell lines Siha, Hela and cervical epithelial immortalized cell line H8 were detected by Real-time PCR. The Tim-4 lentiviral vector was transfected into Siha cell line. The over-expression of Tim-4 in Siha cell line was detected by fluorescence microscopy. The effects of Tim-4 on the invasion and migration of cervical cancer cell line were detected by Transwell and scratches methods. The changes of MMP2, MMP9, E-cadherin and N-cadherin in Siha cells were detected by Western blotting. Results：The expression of Tim-4 was higher in Siha and Hela cell lines compared to that in the H8 cell line. The Siha cell line burdening Tim-4 lentiviral vector was successfully constructed. Over-expression of Tim-4 significantly inhibited the migration and invasion of cervical cancer cell line, and affected the expression of MMP2, MMP9, N-cadherin and E-cadherin. Conclusion：Over-expression of Tim-4 promotes the invasion and migration by regulating the EMT transformation in cervical cell carcinoma.

Novel Coronavirus Pneumonia (NCP) is a class B infectious disease, which is prevented and controlled according to class A infectious diseases. Recently, children′s NCP cases have gradually increased, and children′s fever outpatient department has become the first strategic pass to stop the epidemic. Strengthening the management of the fever diagnosis process is very important for early detection of suspected children, early isolation, early treatment and prevention of cross-infection. This article proposes prevention and control strategies for fever diagnosis, optimizes processes, prevents cross-infection, health protection and disinfection of medical staff, based on the relevant diagnosis, treatment, prevention and control programs of the National Health and Health Commission and on the diagnosis and treatment experience of experts in various provinces and cities. The present guidance summarizes current strategies on pre-diagnosis; triage, diagnosis, treatment, and prevention of 2019-nCoV infection in common fever, suspected and confirmed children, which provide practical suggestions on strengthening the management processes of children′s fever in outpatient department during the novel coronavirus pneumonia epidemic period.